YM BioSciences (YMI)
YM BioSciences Revenues: 0.382M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
YMI Revenues Rankings
| Overall | 1st percentile | 4358 of 4430 |
| Sector | 7th percentile | 437 of 471 in Healthcare |
| Industry | 14th percentile | 113 of 132 in Biotechnology |
YMI Revenues Range, Past 5 Years
| Minimum | 0.246M | Sep 2011 |
| Maximum | 1.98M | Jun 2008 |
| Average | 0.9599M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these YMI related companies
YMI News
$YMI in really good shape and going down... somebody playing with it? Keep going, it will go up withing a week
about 5 days ago by monteazul
about 5 days ago by monteazul
These Biotechs May Break Out While $VVUS And $ARNA Battle It Out. $ASTX $YMI http://stks.co/40Il
about 6 days ago by abubnic
about 6 days ago by abubnic
RT @adamfeuerstein RA Capital goes in for 3M shares of $BCRX during Q1. Also 2.3M shares of $YMI and smallish 300K shares of $VVUS. 13F
about 18 days ago by WolfsBiotechs
about 18 days ago by WolfsBiotechs
$YMI http://stks.co/3ns1 Bullish breakout from consolidation area. Multiple time frames in alignment.
about 20 days ago by redline67
about 20 days ago by redline67
YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
May 11, 7:00AM PR Newswire
May 11, 7:00AM PR Newswire
$YMI after more than a month is getting up the SMA50 which good volumen. Will it last?
about 33 days ago by monteazul
about 33 days ago by monteazul
Bullish engulfing pattern $Ipsu $hdy $ypf $ymi showing strength building. (not in any of them)..... yet
about 37 days ago by Good2go
about 37 days ago by Good2go
Anyone out their know whats going on with $YMI it seems to have stalled
about 46 days ago by jlmvette
about 46 days ago by jlmvette
$YMI on watch for next couple days-- 4$ tgts out there/ over 2.40 could rip
about 68 days ago by ChiBullsTrader
about 68 days ago by ChiBullsTrader
anything I should now about it? RT @Mahmissa Bought ystday afternoon. Also bought small $YMI 1.83
about 74 days ago by monteazul
about 74 days ago by monteazul
$YMI volume is steady after morning selloff, now up again for the next few days. Next step is 2.26 (SMA200)
about 100 days ago by monteazul
about 100 days ago by monteazul
$YMI looks like the offering news brought on some nice volume this morning so far!!
about 100 days ago by TraderTony
about 100 days ago by TraderTony
$YMI would be rather strange to see this hit =< $2.10 this morning
about 100 days ago by TraderTony
about 100 days ago by TraderTony
Interesting, this is certainly not a normal trend by any means!!! RT @BioRunUp $YMI $2.04, down only $.01 after yesterdays ~25% dilution...
about 100 days ago by TraderTony
about 100 days ago by TraderTony
That seems to be a good reaction even though the stock offering RT @BioRunUp $YMI $2.04, down only $.01 after yesterdays ~25% dilution...
about 100 days ago by monteazul
about 100 days ago by monteazul
RT @Benzinga - $YMI Prices $70 Million Public Offering of at $2.00 per Share // IPO to watch $$
about 100 days ago by WorldJazz59
about 100 days ago by WorldJazz59
YM BioSciences Announces Proposed Public Offering of Common Shares; Size Not Given
Feb 23, 4:02PM Benzinga
Feb 23, 4:02PM Benzinga
YM Biosciences rallies 23% after announcing JAK1/JAK2 inhibitor results
Dec 13, 9:00AM theflyonthewall.com
Dec 13, 9:00AM theflyonthewall.com
YM BioSciences (YMI) Reports Update from Phase I/II Data From Its JAK1/JAK2 Inhibitor CYT387 at ASH 2011
Dec 12, 5:04PM Street Insider
Dec 12, 5:04PM Street Insider
YM BioSciences (YMI) Not Aware of Any Reason Behind Unusual Stock Movement
Nov 22, 2:53PM Street Insider
Nov 22, 2:53PM Street Insider
YM Biosciences unaware of material developments influencing trading activity
Nov 22, 2:49PM FlyOnTheWall
Nov 22, 2:49PM FlyOnTheWall
YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2012
Nov 11, 7:00AM PR Newswire
Nov 11, 7:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| YMI | 1.96 | -0.01 | -0.51% | 297.35M |
| YHOO | 14.92 | -0.32 | -2.10% | 18.11B |
| YGE | 2.68 | +0.08 | +3.08% | 390.18M |
| XRA | 2.04 | +0.22 | +12.09% | 179.23M |
| XPO | 17.10 | -0.76 | -4.26% | 143.13M |
| XPL | 1.07 | +0.07 | +7.00% | 36.63M |
| XPH | 54.39 | -1.22 | -2.19% | |
| XOXO | 8.59 | -0.24 | -2.72% | 231.59M |
| XOP | 45.47 | -2.46 | -5.13% | |
| XOMA | 2.36 | -0.03 | -1.26% | 160.57M |
